Daily non-political popular news in brief.

Sutent achieves first line EAU approval for kidney cancer

Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.

Read more »

Keywords: sutent, achieves, line, eau, approval, kidney, cancer, achieve

« Previous | Next »

Similar news on "Sutent achieves first line EAU approval for kidney cancer":

1. Studies suggest key correlation between lung cancer subtype and treatment outcomes
   09-26-2007 · EurekAlert!
   In clinical research, patients with advanced non-small cell lung cancer that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel.
   Similar news · Read more »
   
2. Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
   06-02-2007 · EurekAlert!
   An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a phase II clinical trial at the University of Texas M. D. Anderson Cancer Center.
   Similar news · Read more »
   
3. Cryoablation continues to show good results for kidney cancer patients
   11-25-2007 · EurekAlert!
   A review of 62 Mayo Clinic patients who underwent cryoablation to treat cancerous kidney tumors shows that the patients are cancer free for up to two and a half years after having had the procedure.
   Similar news · Read more »
   
4. Colon cancer screening -- Going 'Back To The Future'?
   02-19-2007 · EurekAlert!
   In an editorial in the February 20 edition of the Annals of Internal Medicine, Indiana University School of Medicine gastroenterologist and Regenstrief Institute, Inc. researcher Thomas Imperiale, M.D., writes that to increase screening rates for colorectal cancers, we need more convenient and less invasive screening tests. An infrequently used type of fecal sampling test, which has had Federal Drug Administration approval since 2001, may meet that need he says.
   Similar news · Read more »
   
5. Follow-up endoscopic surveillance in colorectal cancer patients improves survival
   03-15-2007 · EurekAlert!
   Colorectal cancer patients who undergo colonoscopic surveillance during follow-up after surgery experience improved survival, according to a study to be published in the April issue of Clinical Gastroenterology and Hepatology but currently available on-line.
   Similar news · Read more »
   
6. Jefferson oncologists show breast cancers to be more aggressive in African-American women
   07-09-2007 · EurekAlert!
   A study of more than 2,200 women shows that African-Americans have more advanced breast cancer at the time of diagnosis than Caucasians. African-American women tend to have breast cancer tumor types that are more aggressive and have poorer prognoses. The findings are in line with other recent studies, and provide more evidence of the continuing need for early breast cancer screening for African-American women and the development of individual treatment strategies.
   Similar news · Read more »
   
7. OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer
   10-28-2007 · EurekAlert!
   Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer. "Surgery and radiotherapy shows an early response benefit. It shows that the addition of radiation is potentially reasonable for the first-line treatment," said Clifton David Fuller, M.D., Ph.D., principal investigator of the study.
   Similar news · Read more »
   
8. Freezing bone cancer tumors reduces pain, Mayo Clinic study shows
   11-27-2007 · EurekAlert!
   Cryoablation, a procedure most commonly associated with destroying kidney and prostate tumors by freezing them, has been shown to offer durable pain relief of cancer that has spread to bone.
   Similar news · Read more »
   
9. Northwestern Memorial trial may wean kidney transplant patients off antirejection drugs
   01-22-2008 · EurekAlert!
   After transplant surgery, antirejection drugs for the organ recipient are a must. But prolonged use can have serious side effects, including infections, heart disease and even cancer. A team of researchers at Northwestern University's Feinberg School of Medicine is working with Northwestern Memorial Hospital's department of organ transplantation in a new study that seeks to eliminate the need for antirejection drugs by transplanting stem cells from a kidney donor's bone marrow into the organ recipient.
   Similar news · Read more »
   
10. Scientists find new agent to fight genetic disorders -- Zorro-Locked Nucleic Acid
    04-30-2007 · EurekAlert!
    A new agent, "Zorro-LNA," may stop some genetic disorders in their tracks. An article appearing in The FASEB Journal's June 2007 issue describes how researchers developed Zorro-LNA to bind with both strands of a gene's DNA, effectively disabling it. This has clinical implications for virtually every condition caused or worsened by dominant defective genes, such as: Huntington's disease, familial high cholesterol, polycystic kidney disease, some instances of glaucoma and colorectal cancer, and neurofibromatosis, among others.
    Similar news · Read more »